Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
BioTheranostics’ Prostate Cancer Index is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk of recurrence and metastasis in patients with prostate cancer, according to a study published online in the Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1215870110. Epub March 26, 2013).
BD Diagnostics in April announced an international distributor agreement with Bruker Daltonics to sell and provide frontline technical support for the co-labeled BD Bruker MALDI Biotyper system. The system, combined with automated antimicrobial susceptibility testing on the BD Phoenix microbiology system and BD EpiCenter microbiology data management system, will facilitate a fully integrated, optimized approach for laboratory workflow.
Streck’s CD-Chex CD117 is a flow cytometry control for CD117. The control eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, saving time and money. CD-Chex CD117 is designed to represent abnormal peripheral blood leukocytes similar to a hematolymphoid neoplastic patient sample. The product has surface CD117 that is detectable with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are distinguishable from normal leukocytes on the basis of light-scatter properties, a low level of CD45 expression, and heterogeneous CD117 expression.
BioFire Diagnostics has submitted to the FDA its FilmArray blood culture identification (BCID) panel. The panel received the CE Mark earlier this month. The submission comes after completion of clinical trials for the FilmArray BCID panel, which provides automatic results for common infectious causes of sepsis. BioFire anticipates commercial release of the panel this summer, pending FDA clearance.
Randox Toxicology has developed an ELISA that targets UR-144, XLR-11, and additional synthetic cannabinoid compounds, which are commonly found in new “Spice” and “K2” blends. Together with the company’s JWH/AM2201 synthetic cannabinoids ELISA, the UR-144/XLR-11 ELISA provides a comprehensive solution for the rapid detection of more than 55 current synthetic cannabinoids in urine, blood, and oral fluid.
The Center for Phlebotomy Education is holding the Phlebotomy Supervisor’s Boot Camp July 10-12 and Nov. 6-8 in Louisville, Ky. Educators, phlebotomy supervisors, and lab managers who attend will acquire new skills and strategies for staff development, technical instruction, mentoring, and coaching professionalism. The presenters are Catherine Ernst, RN, PBT(ASCP), Lisa Steinam, PBT(ASCP), and Dennis Ernst, MT(ASCP).
With a recent software upgrade (V2.5/2.3.0.0) and new adapter for its Clinitek Status Connect urine chemistry system, Siemens Healthcare Diagnostics now offers hospitals and clinicians seamless wireless connectivity and improved bar-coding capabilities for point-of-care urinalysis testing. These enhancements enable greater flexibility, risk management, and speed.
Eppendorf North America’s Mastercycler Nexus X1 provides researchers with increased heating and cooling rates by uniting the software with a fast 96-well block. All this is achieved while maintaining low power consumption and low noise emission levels, making the instrument suitable for life science laboratories.
Audit MicroControls’ MicroLQ serum protein control, two levels, is intended to simulate human patient serum samples to monitor the precision of laboratory testing procedures for albumin, alpha1-acid glycoprotein, alpha1-antitrypsin, alpha2-macroglobulin, antithrombin, beta2 microglobulin, ceruloplasmin, complement C3, complement C4, haptoglobin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin M, prealbumin, total protein, and transferrin.
Pathwork Diagnostics has entered into an agreement with Kindstar Global to provide Kindstar with the FDA-cleared IVD kit version of the Pathwork Tissue of Origin Test. The agreement expands Pathwork’s international network of test and service providers and is the first IVD kit agreement for Pathwork.
